Hormonal
Screening for dysglycemia (specifically using OGTT to detect impaired glucose tolerance) in patients with coronary artery disease significantly reduces long-term cardiovascular mortality and major adverse cardiovascular events compared to standard care that relies on fasting glucose or HbA1c alone.
If you have heart disease or are at high risk, ask your doctor for an Oral Glucose Tolerance Test (OGTT), not just a fasting blood sugar or A1c. Standard tests often miss 'Impaired Glucose Tolerance' (IGT), which significantly increases your risk of heart attack and death. Detecting this early allows for treatments (like specific glucose-lowering drugs with heart benefits) that can close the survival gap between diabetic and non-diabetic heart patients.
The GAMI population was followed over a median time of 11.6 years: Both newly detected type 2 diabetes and IGT were associated with a considerably worse cardiovascular prognosis than that seen among patients with a normal glucose metabolism... The dismal prognostic implication of newly detected IGT among patients with acute coronary syndromes... has also been confirmed by George et al. and Chattopadhyay et al.
Why this rating
Based on multiple observational cohorts (GAMI, Euro Heart Survey, China Heart Survey) and long-term follow-up, though not a single massive RCT for screening itself.
Source
Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management
Giulia Ferrannini et al. · Diabetes Care · 2020
DOI 10.2337/dci20-0002
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →